1083 related articles for article (PubMed ID: 26599300)
1. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
3. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
[TBL] [Abstract][Full Text] [Related]
4. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
5. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
[TBL] [Abstract][Full Text] [Related]
6. Changes of cerebrospinal fluid Aβ
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Nov; 38(11):1953-1961. PubMed ID: 28808876
[TBL] [Abstract][Full Text] [Related]
7. CSF biomarkers and clinical progression of Parkinson disease.
Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
[TBL] [Abstract][Full Text] [Related]
10. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
11. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
12. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L
JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
[TBL] [Abstract][Full Text] [Related]
17. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
[TBL] [Abstract][Full Text] [Related]
18. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
[TBL] [Abstract][Full Text] [Related]
19. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
20. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
Delgado-Alvarado M; Dacosta-Aguayo R; Navalpotro-Gómez I; Gago B; Gorostidi A; Jiménez-Urbieta H; Quiroga-Varela A; Ruiz-Martínez J; Bergareche A; Rodríguez-Oroz MC
Mov Disord; 2018 Nov; 33(11):1809-1813. PubMed ID: 30423201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
